Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

Charles A. Mack, Wen Ru Song, Heather Carpenter, Tom J. Wickham, Imre Kovesdi, Ben Gary Harvey, Christopher J. Magovern, O. Wayne Isom, Todd Rosengart, Eric Falck-Pedersen, Neil R. Hackett, Ronald Crystal, Andrea Mastrangeli

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Effective gene transfer and expression following repetitive administration of adenoviral (Ad) vectors in experimental animals is limited by anti-Ad neutralizing antibodies. Knowing that anti-Ad humoral immunity is serotype-specific, we hypothesized that anti-Ad neutralizing immunity could be circumvented using Ad vectors of different serotypes (Ad2, Ad5) within the same subgroup (C) to transfer and express β-glucuronidase (βglu) in the lung. Sprague-Dawley rats received an intratracheal administration of either Ad2βglu or Ad5βglu, and, 14 days later, repeat administration of either the same vector or a vector of a different serotype. Analysis of serum and bronchoalveolar lavage fluid following initial vector administration demonstrated systemic and local serotype-specific neutralizing antibodies. For both the Ad2 and Ad5 vectors, βglu expression 24 hr following the second administration of the same serotype was < 30% of that of naive animals. In contrast, βglu expression 24 hr following second administration of a different serotype Ad vector was similar to expression at 24 hr of naive animals receiving a single administration (Ad5βglu followed by Ad2βglu, as well as Ad2βglu followed by Ad5βglu;p > 0.2 both comparisons). Although the alternative serotype bypassed anti-Ad neutralizing immunity, persistence of expression was reduced compared to that following administration to naive animals. Compatible with this observation, systemic administration of the same vectors to C57B1/6 mice demonstrated induction of cytotoxic T lymphocytes directed against the βglu transgene, as well as products of the Ad genome. Interestingly, intratracheal administration of vectors with different serotypes and different transgenes to rats resulted in longer expression (but still not normalized) compared to that achieved with vectors of different serotypes but the same transgene. These observations demonstrate that alternate use of Ad vectors from different serotypes within the same subgroup can circumvent anti-Ad humoral immunity to permit effective gene transfer after repeat administration, although the chronicity of expression is limited, likely by cellular immune processes directed against both the transgene and viral gene products expressed by the vector.

Original languageEnglish
Pages (from-to)99-109
Number of pages11
JournalHuman Gene Therapy
Volume8
Issue number1
DOIs
Publication statusPublished - 1 Jan 1997
Externally publishedYes

Fingerprint

Adenoviridae
Immunity
Transgenes
Glucuronidase
Humoral Immunity
Neutralizing Antibodies
Serogroup
Bronchoalveolar Lavage Fluid
Cytotoxic T-Lymphocytes
Viral Proteins
Sprague Dawley Rats
Genome
Gene Expression
Lung
Serum
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Mack, C. A., Song, W. R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B. G., ... Mastrangeli, A. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Human Gene Therapy, 8(1), 99-109. https://doi.org/10.1089/hum.1997.8.1-99

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. / Mack, Charles A.; Song, Wen Ru; Carpenter, Heather; Wickham, Tom J.; Kovesdi, Imre; Harvey, Ben Gary; Magovern, Christopher J.; Isom, O. Wayne; Rosengart, Todd; Falck-Pedersen, Eric; Hackett, Neil R.; Crystal, Ronald; Mastrangeli, Andrea.

In: Human Gene Therapy, Vol. 8, No. 1, 01.01.1997, p. 99-109.

Research output: Contribution to journalArticle

Mack, CA, Song, WR, Carpenter, H, Wickham, TJ, Kovesdi, I, Harvey, BG, Magovern, CJ, Isom, OW, Rosengart, T, Falck-Pedersen, E, Hackett, NR, Crystal, R & Mastrangeli, A 1997, 'Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype', Human Gene Therapy, vol. 8, no. 1, pp. 99-109. https://doi.org/10.1089/hum.1997.8.1-99
Mack, Charles A. ; Song, Wen Ru ; Carpenter, Heather ; Wickham, Tom J. ; Kovesdi, Imre ; Harvey, Ben Gary ; Magovern, Christopher J. ; Isom, O. Wayne ; Rosengart, Todd ; Falck-Pedersen, Eric ; Hackett, Neil R. ; Crystal, Ronald ; Mastrangeli, Andrea. / Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. In: Human Gene Therapy. 1997 ; Vol. 8, No. 1. pp. 99-109.
@article{9b7772f7db9e40fc905c97f091d89d5d,
title = "Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype",
abstract = "Effective gene transfer and expression following repetitive administration of adenoviral (Ad) vectors in experimental animals is limited by anti-Ad neutralizing antibodies. Knowing that anti-Ad humoral immunity is serotype-specific, we hypothesized that anti-Ad neutralizing immunity could be circumvented using Ad vectors of different serotypes (Ad2, Ad5) within the same subgroup (C) to transfer and express β-glucuronidase (βglu) in the lung. Sprague-Dawley rats received an intratracheal administration of either Ad2βglu or Ad5βglu, and, 14 days later, repeat administration of either the same vector or a vector of a different serotype. Analysis of serum and bronchoalveolar lavage fluid following initial vector administration demonstrated systemic and local serotype-specific neutralizing antibodies. For both the Ad2 and Ad5 vectors, βglu expression 24 hr following the second administration of the same serotype was < 30{\%} of that of naive animals. In contrast, βglu expression 24 hr following second administration of a different serotype Ad vector was similar to expression at 24 hr of naive animals receiving a single administration (Ad5βglu followed by Ad2βglu, as well as Ad2βglu followed by Ad5βglu;p > 0.2 both comparisons). Although the alternative serotype bypassed anti-Ad neutralizing immunity, persistence of expression was reduced compared to that following administration to naive animals. Compatible with this observation, systemic administration of the same vectors to C57B1/6 mice demonstrated induction of cytotoxic T lymphocytes directed against the βglu transgene, as well as products of the Ad genome. Interestingly, intratracheal administration of vectors with different serotypes and different transgenes to rats resulted in longer expression (but still not normalized) compared to that achieved with vectors of different serotypes but the same transgene. These observations demonstrate that alternate use of Ad vectors from different serotypes within the same subgroup can circumvent anti-Ad humoral immunity to permit effective gene transfer after repeat administration, although the chronicity of expression is limited, likely by cellular immune processes directed against both the transgene and viral gene products expressed by the vector.",
author = "Mack, {Charles A.} and Song, {Wen Ru} and Heather Carpenter and Wickham, {Tom J.} and Imre Kovesdi and Harvey, {Ben Gary} and Magovern, {Christopher J.} and Isom, {O. Wayne} and Todd Rosengart and Eric Falck-Pedersen and Hackett, {Neil R.} and Ronald Crystal and Andrea Mastrangeli",
year = "1997",
month = "1",
day = "1",
doi = "10.1089/hum.1997.8.1-99",
language = "English",
volume = "8",
pages = "99--109",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

AU - Mack, Charles A.

AU - Song, Wen Ru

AU - Carpenter, Heather

AU - Wickham, Tom J.

AU - Kovesdi, Imre

AU - Harvey, Ben Gary

AU - Magovern, Christopher J.

AU - Isom, O. Wayne

AU - Rosengart, Todd

AU - Falck-Pedersen, Eric

AU - Hackett, Neil R.

AU - Crystal, Ronald

AU - Mastrangeli, Andrea

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Effective gene transfer and expression following repetitive administration of adenoviral (Ad) vectors in experimental animals is limited by anti-Ad neutralizing antibodies. Knowing that anti-Ad humoral immunity is serotype-specific, we hypothesized that anti-Ad neutralizing immunity could be circumvented using Ad vectors of different serotypes (Ad2, Ad5) within the same subgroup (C) to transfer and express β-glucuronidase (βglu) in the lung. Sprague-Dawley rats received an intratracheal administration of either Ad2βglu or Ad5βglu, and, 14 days later, repeat administration of either the same vector or a vector of a different serotype. Analysis of serum and bronchoalveolar lavage fluid following initial vector administration demonstrated systemic and local serotype-specific neutralizing antibodies. For both the Ad2 and Ad5 vectors, βglu expression 24 hr following the second administration of the same serotype was < 30% of that of naive animals. In contrast, βglu expression 24 hr following second administration of a different serotype Ad vector was similar to expression at 24 hr of naive animals receiving a single administration (Ad5βglu followed by Ad2βglu, as well as Ad2βglu followed by Ad5βglu;p > 0.2 both comparisons). Although the alternative serotype bypassed anti-Ad neutralizing immunity, persistence of expression was reduced compared to that following administration to naive animals. Compatible with this observation, systemic administration of the same vectors to C57B1/6 mice demonstrated induction of cytotoxic T lymphocytes directed against the βglu transgene, as well as products of the Ad genome. Interestingly, intratracheal administration of vectors with different serotypes and different transgenes to rats resulted in longer expression (but still not normalized) compared to that achieved with vectors of different serotypes but the same transgene. These observations demonstrate that alternate use of Ad vectors from different serotypes within the same subgroup can circumvent anti-Ad humoral immunity to permit effective gene transfer after repeat administration, although the chronicity of expression is limited, likely by cellular immune processes directed against both the transgene and viral gene products expressed by the vector.

AB - Effective gene transfer and expression following repetitive administration of adenoviral (Ad) vectors in experimental animals is limited by anti-Ad neutralizing antibodies. Knowing that anti-Ad humoral immunity is serotype-specific, we hypothesized that anti-Ad neutralizing immunity could be circumvented using Ad vectors of different serotypes (Ad2, Ad5) within the same subgroup (C) to transfer and express β-glucuronidase (βglu) in the lung. Sprague-Dawley rats received an intratracheal administration of either Ad2βglu or Ad5βglu, and, 14 days later, repeat administration of either the same vector or a vector of a different serotype. Analysis of serum and bronchoalveolar lavage fluid following initial vector administration demonstrated systemic and local serotype-specific neutralizing antibodies. For both the Ad2 and Ad5 vectors, βglu expression 24 hr following the second administration of the same serotype was < 30% of that of naive animals. In contrast, βglu expression 24 hr following second administration of a different serotype Ad vector was similar to expression at 24 hr of naive animals receiving a single administration (Ad5βglu followed by Ad2βglu, as well as Ad2βglu followed by Ad5βglu;p > 0.2 both comparisons). Although the alternative serotype bypassed anti-Ad neutralizing immunity, persistence of expression was reduced compared to that following administration to naive animals. Compatible with this observation, systemic administration of the same vectors to C57B1/6 mice demonstrated induction of cytotoxic T lymphocytes directed against the βglu transgene, as well as products of the Ad genome. Interestingly, intratracheal administration of vectors with different serotypes and different transgenes to rats resulted in longer expression (but still not normalized) compared to that achieved with vectors of different serotypes but the same transgene. These observations demonstrate that alternate use of Ad vectors from different serotypes within the same subgroup can circumvent anti-Ad humoral immunity to permit effective gene transfer after repeat administration, although the chronicity of expression is limited, likely by cellular immune processes directed against both the transgene and viral gene products expressed by the vector.

UR - http://www.scopus.com/inward/record.url?scp=16944367354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944367354&partnerID=8YFLogxK

U2 - 10.1089/hum.1997.8.1-99

DO - 10.1089/hum.1997.8.1-99

M3 - Article

C2 - 8989999

AN - SCOPUS:16944367354

VL - 8

SP - 99

EP - 109

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -